<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="235">
  <!-- This xml conforms to:  http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>Information obtained from ClinicalTrials.gov on October 20, 2011</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01190930</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000683227</org_study_id>
    <secondary_id>COG-AALL0932</secondary_id>
    <nct_id>NCT01190930</nct_id>
  </id_info>
  <brief_title>Risk-Adapted Chemotherapy in Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia</brief_title>
  <official_title>Treatment of Patients With Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <authority>Unspecified</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer
      cells, either by killing the cells or by stopping them from dividing. Giving more than one
      drug (combination chemotherapy), giving the drugs in different doses, and giving the drugs
      in different combinations may kill more cancer cells.

      PURPOSE: This partially randomized phase III clinical trial is studying different
      combinations of risk-adapted chemotherapy regimens and their side effects and comparing how
      well they work in treating younger patients with newly diagnosed standard-risk acute
      lymphoblastic leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To determine if a maintenance regimen containing once weekly oral methotrexate at 40
           mg/m^2/week will result in an improved disease-free survival (DFS) compared to that
           containing weekly oral methotrexate at 20 mg/m^2/week in the average-risk (AR) subset
           of pediatric patients with standard-risk (SR) B-precursor acute lymphoblastic leukemia
           (ALL).

        -  To determine whether a reduced-pulses maintenance regimen with vincristine
           sulfate/dexamethasone pulses delivered every 12 weeks can be used without adversely
           impacting DFS as compared to pulses given every 4 weeks in the AR subset of patients
           with SR B-precursor ALL.

        -  To confirm that patients in the low-risk (LR) subset of SR B-precursor ALL, based on
           clinical and cytogenetic features and minimal residual disease (MRD) criteria, can
           attain a 5-year DFS of ≥ 95% with either a P9904-based regimen that includes 6 courses
           of intermediate dose (1 g/m^2 over 24 hours) methotrexate without alkylating agents or
           anthracyclines (Arm LR-M), or an outpatient-based regimen identical to that of AR
           patients with reduced vincristine sulfate/dexamethasone pulses at 12-week intervals
           during maintenance (Arm LR-C).

        -  To provide standardized treatment and enhanced supportive care to children with SR Down
           syndrome-ALL in order to improve outcomes and facilitate further study of this
           biologically and clinically unique patient subgroup.

      Secondary

        -  To assess the burden of AR-ALL therapy as measured by surveys of the child's quality of
           life, missed days of school/daycare/work by children and parents, family functioning,
           parental perception of the child's health vulnerability, physical functioning, and
           emotional distress overall at different time points during and at the end of therapy.

        -  To assess the burden of AR-ALL therapy as measured by surveys of the child's quality of
           life, missed days of school/daycare/work by children and parents, family functioning,
           parental perception of the child's health vulnerability, physical functioning, and
           emotional distress by comparing children randomized to every 4-week vs every 12-week
           dexamethasone/vincristine sulfate pulses during maintenance therapy.

        -  To characterize the onset, severity, and natural history of vincristine-associated
           neuropathy by physical therapists (or occupational therapists) in children undergoing
           therapy for AR-ALL, 1) overall at different time points during and at the end of
           therapy, and by 2) comparing children randomized to every 4 weeks vs every 12 weeks
           dexamethasone/vincristine pulses during Maintenance.

      OUTLINE: This is a multicenter study.

      All patients receive induction therapy comprising intrathecal (IT) cytarabine on day 1;
      vincristine sulfate IV on days 1, 8, 15, and 22; dexamethasone orally or IV twice daily
      (BID) on days 1-28; pegaspargase IV over 1-2 hours on day 4; and IT methotrexate* on days 8
      and 29. Patients with Philadelphia chromosome-positive disease are eligible to transfer to
      COG-AALL0622 by day 15 of induction therapy and patients with high-risk (HR) or very
      high-risk (VHR) disease are eligible to transfer to a COG HR or VHR trial at the end of
      induction therapy. Patients with standard-risk disease with Down syndrome (DS) who have bone
      marrow minimal residual disease ≥ 0.01% are eligible to transfer to the DS stratum of the HR
      trial. Patients with induction failure (defined as M3 [&gt; 25% lymphoblasts] on day 29) may be
      eligible for the COG VHR-acute lymphoblastic leukemia study.

      NOTE: *Patients with DS also receive oral leucovorin calcium every 12 hours on days 10-11
      and 31-32.

        -  Standard-risk with Down syndrome:

             -  Consolidation therapy (4 weeks): Patients receive vincristine sulfate IV on day 1;
                oral mercaptopurine on days 1-28; IT methotrexate on days 1, 8, and 15; and oral
                leucovorin calcium every 12 hours on days 3-4, 10-11, and 17-18.

             -  Interim maintenance I therapy (8 weeks): Patients receive vincristine sulfate IV
                and methotrexate IV over 2-15 minutes on days 1, 11, 21, 31, and 41; IT
                methotrexate on day 31; and oral leucovorin calcium every 12 hours on days 36-34.

             -  Delayed-intensification therapy (8 weeks): Patients receive dexamethasone orally
                or IV BID on days 1-7 and 15-21; vincristine sulfate IV and doxorubicin
                hydrochloride IV over 1-15 minutes on days 1, 8, and 15; pegaspargase IV over 1-2
                hours on day 4; cyclophosphamide IV over 30-60 minutes on day 29; oral thioguanine
                on days 29-42; cytarabine IV over 15-30 minutes or subcutaneously (SC) on days
                29-32 and 33-39; IT methotrexate on days 1 and 29; and oral leucovorin calcium
                every 12 hours on days 3-4 and 31-32.

             -  Interim maintenance II therapy (8 weeks): Patients receive vincristine sulfate IV
                and methotrexate IV over 2-15 minutes on days 1, 11, 21, 31, and 41; IT
                methotrexate on days 1 and 31; and oral leucovorin calcium every 12 hours on days
                3-4 and 33-34.

             -  Maintenance therapy: Patients receive vincristine sulfate IV on day 1; oral
                dexamethasone BID on days 1-5; oral methotrexate on days 8, 15, 22, 29, 36, 43,
                50, 57, 64, 71, and 78; oral mercaptopurine on days 1-84; and IT methotrexate on
                day 1. Courses repeat every 12 weeks for 2 years (timed from the start of interim
                maintenance I therapy).

        -  Average-risk:

             -  Consolidation therapy (4 weeks): Patients receive vincristine sulfate IV on day 1;
                oral mercaptopurine on days 1-28; and IT methotrexate on days 1, 8, and 15.

             -  Interim maintenance I therapy (8 weeks): Patients receive vincristine sulfate IV
                and methotrexate IV over 2-15 minutes on days 1, 11, 21, 31, and 41 and IT
                methotrexate on day 31.

             -  Delayed intensification therapy (8 weeks): Patients receive dexamethasone orally
                or IV BID on days 1-7 and 15-21; vincristine sulfate IV and doxorubicin
                hydrochloride IV over 1-15 minutes on days 1, 8, and 15; pegaspargase IV over 1-2
                hours on day 4; cyclophosphamide IV over 30-60 minutes on day 29; oral thioguanine
                on days 29-42; cytarabine IV over 15-30 minutes or SC on days 29-32 and 36-39; and
                IT methotrexate on days 1 and 29.

             -  Interim maintenance II therapy (8 weeks): Patients receive vincristine sulfate IV
                and methotrexate IV over 2-15 minutes on days 1, 11, 21, 31, and 41 and IT
                methotrexate on days 1 and 31.

             -  Maintenance therapy: Patients are randomized to 1 of 4 maintenance therapy
                treatment arms.

                  -  Arm A: Patients receive vincristine sulfate IV on days 1, 29, and 57; oral
                     dexamethasone BID on days 1-5, 29-33, and 57-61; oral methotrexate on days 8,
                     15, 22, 29, 36, 43, 50, 57, 64, 71, and 78; oral mercaptopurine on days 1-84;
                     and IT methotrexate on day 1.

                  -  Arm B: Patients receive vincristine sulfate IV on days 1, 29, and 57; oral
                     dexamethasone BID on days 1-5, 29-33, and 57-61; higher-dose oral
                     methotrexate on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78; oral
                     mercaptopurine on days 1-84; and IT methotrexate on day 1.

                  -  Arm C: Patients receive vincristine sulfate IV on day 1; oral dexamethasone
                     BID on days 1-5; oral methotrexate on days 8, 15, 22, 29, 36, 43, 50, 57, 64,
                     71, and 78; oral mercaptopurine on days 1-84; and IT methotrexate on day 1.

                  -  Arm D: Patients receive vincristine sulfate IV on day 1; oral dexamethasone
                     BID on days 1-5; higher-dose oral methotrexate on days 8, 15, 22, 29, 36, 43,
                     50, 57, 64, 71, and 78; oral mercaptopurine on days 1-84; and IT methotrexate
                     on day 1.

      In all arms, maintenance therapy courses repeat every 12 weeks for 2 years for girls and for
      3 years for boys (timed from the start of interim maintenance I therapy).

        -  Low-risk: Patients are randomized to 1 of 2 treatment arms.

             -  Arm I (LR-M):

                  -  Consolidation therapy (19 weeks): Beginning one week after completion of
                     induction therapy, patients receive vincristine sulfate IV on days 15, 22,
                     78, and 85; methotrexate IV over 24 hours and IT methotrexate on days 8, 29,
                     50, 71, 92, and 113; leucovorin calcium orally or IV on days 9-10, 30-31,
                     51-52, 72-73, 93-94, and 114-115; dexamethasone orally or IV BID on days
                     15-21 and 78-84; and oral mercaptopurine on days 1-133.

                  -  Maintenance therapy: Patients receive vincristine sulfate IV on days 1 and 8;
                     oral dexamethasone BID on days 1-7; oral methotrexate* on days 1, 8, 15, 22,
                     29, 36, 43, 50, 57, 64, 71, 78, 85, 92, 99, and 106; and oral mercaptopurine
                     on days 1-112. Courses repeat every 16 weeks. Patients also receive IT
                     methotrexate on days 1 and 85 (courses 1 and 4), day 57 (courses 2 and 5), or
                     day 29 (courses 3 and 6). Patients then receive course 7 comprising
                     vincristine sulfate IV on days 1 and 8; oral dexamethasone BID on days 1-7;
                     oral methotrexate on days 1, 8, 15, 22, 29, 36, 43, 50, 57, and 64; and oral
                     mercaptopurine on days 1-70. Treatment continues for 2½ years (timed from the
                     date of diagnosis).

      NOTE: *Patients do not receive oral methotrexate on the days that they receive IT
      methotrexate.

        -  Arm II (LR-C):

             -  Consolidation therapy (4 weeks): Patients receive vincristine sulfate IV on day 1;
                oral mercaptopurine on days 1-28; and IT methotrexate on days 1, 8, and 15.

             -  Interim maintenance I therapy (8 weeks): Patients receive vincristine sulfate IV
                and methotrexate IV over 2-15 minutes on days 1, 11, 21, 31, and 41 and IT
                methotrexate on day 31.

             -  Delayed-intensification therapy (8 weeks): Patients receive dexamethasone orally
                or IV BID on days 1-7 and 15-21; vincristine sulfate IV and doxorubicin
                hydrochloride IV over 1-15 minutes on days 1, 8, and 15; pegaspargase IV over 1-2
                hours on day 4; cyclophosphamide IV over 30-60 minutes on day 29; oral thioguanine
                on days 29-42; cytarabine IV over 15-30 minutes or SC on days 29-32 and 36-39; and
                IT methotrexate on days 1 and 29.

             -  Interim maintenance II therapy (8 weeks): Patients receive vincristine sulfate IV
                and methotrexate IV over 2-15 minutes on days 1, 11, 21, 31, and 41 and IT
                methotrexate on days 1 and 31.

             -  Maintenance therapy: Patients receive vincristine sulfate IV on day 1; oral
                dexamethasone BID on days 1-5; oral methotrexate on days 8, 15, 22, 29, 36, 43,
                50, 57, 64, 71, and 78; oral mercaptopurine on days 1-84; and IT methotrexate on
                day 1. Courses repeat every 12 weeks for 2 years for girls and for 3 years for
                boys (timed from the start of interim maintenance I therapy).

      During the Maintenance phase of therapy, health-related quality-of-life (HRQOL) measures,
      parent's perception of child's health vulnerability, fewer missed days of school/daycare by
      patients and work by parents, and peripheral neurological functioning may be compared in
      children receiving different vincristine sulfate/dexamethasone pulses frequencies to
      systematically assess the impact of treatment.

      Blood samples may be collected periodically for research studies and patients may complete
      quality-of-life surveys periodically.

      After completion of study treatment, patients are followed up periodically for 10 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2010</start_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation:  Randomized, Masking:  Open Label, Primary Purpose:  Treatment</study_design>
  <primary_outcome>
    <measure>Improvement in 5-year disease-free survival (DFS) from 93% to 96% in average-risk (AR) patients based on the methotrexate randomization</measure>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of whether the 5-year DFS in AR patients is adversely affected by the reduced pulses in maintenance</measure>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of whether less intensive therapy will maintain a 5-year DFS ≥ 95% for low-risk patients randomized to 1 of 2 low-intensity regimens</measure>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>5-year DFS for Down syndrome patients</measure>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Burden of therapy in AR patients overall at different time points during and at the end of therapy</measure>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Burden of therapy in AR patients randomized to every 4-week vs every 12-week pulses during maintenance therapy</measure>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">5760</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive vincristine sulfate IV on days 1, 29, and 57; oral dexamethasone BID on days 1-5, 29-33, and 57-61; oral methotrexate on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78; oral mercaptopurine on days 1-84; and IT methotrexate on day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive vincristine sulfate IV on days 1, 29, and 57; oral dexamethasone BID on days 1-5, 29-33, and 57-61; higher-dose oral methotrexate on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78;  oral mercaptopurine on days 1-84; and IT methotrexate on day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive vincristine sulfate IV on day 1; oral dexamethasone BID on days 1-5;  oral methotrexate on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78; oral mercaptopurine on days 1-84; and IT methotrexate on day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive vincristine sulfate IV on day 1; oral dexamethasone BID on days 1-5; higher-dose oral methotrexate on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78;  oral mercaptopurine on days 1-84; and IT methotrexate on day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm LR-M</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive consolidation and maintenance therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm LR-C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive consolidation, interim maintenance I, delayed intensification, interim maintenance II, and maintenance therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given IV or orally</description>
    <arm_group_label>Arm LR-C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <description>Given IV or orally</description>
    <arm_group_label>Arm LR-C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>Given IV or orally</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_label>Arm LR-C</arm_group_label>
    <arm_group_label>Arm LR-M</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <description>Given IV or orally</description>
    <arm_group_label>Arm LR-C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
    <description>Given IV or orally</description>
    <arm_group_label>Arm LR-M</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mercaptopurine</intervention_name>
    <description>Given IV or orally</description>
    <arm_group_label>Arm LR-C</arm_group_label>
    <arm_group_label>Arm LR-M</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_label>Arm LR-C</arm_group_label>
    <arm_group_label>Arm LR-M</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegaspargase</intervention_name>
    <description>Given IV or orally</description>
    <arm_group_label>Arm LR-C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thioguanine</intervention_name>
    <description>Given IV or orally</description>
    <arm_group_label>Arm LR-C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
    <description>Given IV or orally</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_label>Arm LR-C</arm_group_label>
    <arm_group_label>Arm LR-M</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Enrolled on COG-AALL08B1

          -  Newly diagnosed B-precursor acute lymphoblastic leukemia (ALL)

               -  NCI standard-risk (SR) disease

          -  Meets the criteria for one of the following risk groups after induction therapy††:

               -  Low-risk (LR) disease, defined as meeting the following criteria:

                    -  Favorable genetics: the presence of simultaneous trisomies of chromosome 4
                       and 10 (double trisomy; DT) or ETV6/RUNX1 fusion

                    -  Day 8 peripheral blood (PB) minimal residual disease (MRD) &lt; 0.01%

                    -  Day 29 bone marrow (BM) MRD &lt; 0.01%

                    -  No CNS2*, CNS3*, or testicular† leukemia

                    -  No steroid pretreatment

                    -  No Down syndrome (DS)

                    -  No unfavorable genetic characteristics, defined as:

                         -  iAMP21 as identified by fluorescence in-situ hybridization (FISH)

                         -  MLL rearrangements as identified by cytogenetics, FISH, or molecular
                            studies

                         -  Hypodiploidy: Fewer than 44 chromosomes and/or DNA index &lt; 0.81, or
                            other clear evidence of a hypodiploid clone

                         -  Induction failure: M3 marrow on Day 29

                         -  Philadelphia chromosome positive (Ph+) ALL

                              -  BCR-ABL1 (formerly known as BCR-ABL) fusion transcript determined
                                 by FISH or RT-PCR

                              -  t(9;22)(q34;q11) determined by cytogenetics

               -  Average-risk disease, defined as meeting one of the following sets of criteria:

                    -  Favorable genetics: the presence of DT or ETV6/RUNX1 fusions

                    -  Day 8 PB MRD ≥ 0.01% or CNS2* status

                    -  Day 29 BM MRD &lt; 0.01%

                    -  No CNS3* or testicular† leukemia

                    -  No DS OR

                    -  Neither favorable nor unfavorable cytogenetics

                    -  Day 8 PB MRD &lt; 1%

                    -  Day 29 BM MRD &lt; 0.01%

                    -  No CNS3* or testicular† leukemia

                    -  No DS

               -  Standard-risk with Down syndrome (DS), defined as meeting the following
                  criteria:

                    -  No mixed-lineage leukemia (MLL)-rearrangement, hypodiploidy, or
                       Philadelphia chromosome-positive (Ph+) disease

                    -  Day 29 BM MRD &lt; 0.01%‡‡

                    -  No CNS3* or testicular† leukemia NOTE: ‡‡DS-ALL patients who have day 29 BM
                       MRD &gt; 0.01% will be eligible for post-induction therapy on the DS stratum
                       of the high-risk trial.

        NOTE: *CNS2 disease is defined as, in cerebrospinal fluid (CSF), presence of &lt; 5/mm3 WBCs
        and cytospin positive for blasts, or traumatic lumbar puncture (LP) ≥ 5/mm3 WBCs cytospin
        positive for blasts, but negative by Steinherz/Bleyer algorithm. CNS3 disease is defined
        as, in CSF, after traumatic LP presence of ≥ 5/mm3 WBCs and cytospin positive for blasts
        and/or clinical signs of CNS leukemia. The CNS status must be determined based on a sample
        obtained before administration of any systemic or intrathecal chemotherapy.

        NOTE: †Testicular leukemia is defined as unilateral or bilateral testiculomegaly. Biopsy
        is required if clinical findings are equivocal or suggestive of hydrocele or a
        non-leukemic blast.

        NOTE: †† Patients entered on this study who are later found to meet eligibility criteria
        for the COG-AALL0622 Ph+ ALL study should be immediately be taken off study therapy before
        day 15 of induction therapy if they are eligible to transfer to COG-AALL06222 or its
        successor study or otherwise, at the end of induction therapy.

          -  Patients enrolled in AALL0932 who are identified to have iAMP21 will be classified as
             Very High Risk and will not be eligible to continue on AALL0932 after Induction
             therapy, but will be eligible to enroll in AALL1131 for post-Induction therapy

        PATIENT CHARACTERISTICS:

          -  WBC count &lt; 50,000/mm^3

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No prior cytotoxic chemotherapy for the current diagnosis of ALL or any cancer
             diagnosed previously

               -  Steroids* and intrathecal cytarabine for the current diagnosis of ALL allowed

                    -  Inhalational steroids are not considered as pretreatment NOTE: *If steroids
                       are given for 24 hours in the 2 weeks before diagnosis and a complete blood
                       count (CBC) is obtained within 3 days before the initiation of the steroid,
                       the patient will be assigned to induction based on NCI risk group using the
                       pre-steroid WBC count. If there is no pre-steroid CBC obtained, the patient
                       will be assigned to receive induction therapy on the COG high-risk study.
                       Post-induction risk assignment will be refined by leukemia-specific genetic
                       features and the level of bone marrow minimal residual disease at day 29,
                       except that SR patients in this group will not be eligible for the LR arm.
                       Any amount of steroid pretreatment at any time before 2 weeks before
                       diagnosis will not affect initial induction assignment as long as the
                       patient meets all other eligibility criteria. SR patients in this group may
                       be eligible for the LR arm only if they did not receive steroids within the
                       month before diagnosis.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>9 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Angiolillo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UAB Comprehensive Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - UAB Comprehensive Cancer Center</last_name>
      <phone>205-934-0309</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of South Alabama Mitchell Cancer Institute</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felicia L. Wilson</last_name>
      <phone>251-405-5115</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Phoenix Children's Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016-7710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica L. Boklan</last_name>
      <phone>602-546-0920</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arizona Cancer Center at University of Arizona Health Sciences Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724-5024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Arizona Cancer Center at University o</last_name>
      <phone>520-626-9008</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arkansas Cancer Research Center at University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trial Office - Arkansas Cancer Research Center at Uni</last_name>
      <phone>501-686-8274</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southern California Permanente Medical Group</name>
      <address>
        <city>Downey</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert M. Cooper</last_name>
      <phone>323-783-5307</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - City of Hope Comprehensive Cancer Cen</last_name>
      <phone>800-826-4673</phone>
      <email>becomingapatient@coh.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Cancer Institute at Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Loma Linda University Cancer Institut</last_name>
      <phone>909-558-3375</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jonathan Jaques Children's Cancer Center at Miller Children's Hospital</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerry Z. Finklestein</last_name>
      <phone>562-728-5000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048-1865</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fataneh (Fae) Majlessipour</last_name>
      <phone>310-423-4423</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Jonsson Comprehensive Cancer Center a</last_name>
      <phone>888-798-0719</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leo Mascarenhas</last_name>
      <phone>323-361-2529</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Central California</name>
      <address>
        <city>Madera</city>
        <state>California</state>
        <zip>93638-8762</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vonda L. Crouse</last_name>
      <phone>559-353-5480</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Violet Shen</last_name>
      <phone>714-532-8636</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lucile Packard Children's Hospital at Stanford University Medical Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>95798</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neyssa M. Marina</last_name>
      <phone>650-723-5535</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Medical Center - Oakland</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95825</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent A. Kiley</last_name>
      <phone>916-474-2326</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California Davis Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - University of California Davis Cancer</last_name>
      <phone>916-734-3089</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital - San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123-4282</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Rady Children's Hospital - San Diego</last_name>
      <phone>858-966-5934</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical  Trials Office - UCSF Helen Diller Family Comprehensi</last_name>
      <phone>877-827-3222</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Santa Barbara Cottage Children's Hospital</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel J. Greenfield</last_name>
      <phone>805-569-8394</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado Center for Cancer and Blood Disorders</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly W. Maloney</last_name>
      <phone>720-777-6673</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Presbyterian - St. Luke's Medical Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Presbyterian - St. Luke's Medical Cen</last_name>
      <phone>303-839-6000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Connecticut Children's Medical Center</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Connecticut Children's Medical Center</last_name>
      <phone>860-545-9967</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520-8028</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Yale Cancer Center</last_name>
      <phone>203-785-5702</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alfred I. duPont Hospital for Children</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Alfred I. duPont Hospital for Childre</last_name>
      <phone>302-651-5755</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010-2970</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Children's National Medical Center</last_name>
      <phone>202-884-2549</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lombardi Comprehensive Cancer Center at Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Lombardi Comprehensive Cancer Center</last_name>
      <phone>202-444-0381</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Broward General Medical Center Cancer Center</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Broward General Medical Center Cancer</last_name>
      <phone>954-355-5346</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lee Cancer Care of Lee Memorial Health System</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Lee Cancer Care of Lee Memorial Healt</last_name>
      <phone>877-680-0008</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Florida Shands Cancer Center</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610-0232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - University of Florida Shands Cancer C</last_name>
      <phone>888-254-7581</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Cancer Institute at Memorial Regional Hospital</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Memorial Cancer Institute</last_name>
      <phone>954-985-3443</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric S. Sandler</last_name>
      <phone>904-697-3793</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baptist-South Miami Regional Cancer Program</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Doured Daghistani</last_name>
      <phone>305-274-1662</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Miami Children's Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrique A. Escalon</last_name>
      <phone>305-662-8360x4960</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Miami Sylvester Comprehensive Cancer Center - Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>University of Miami Sylvester Comprehensive Cancer Center Clin</last_name>
      <phone>866-574-5124</phone>
      <email>Sylvester@emergingmed.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>M.D. Anderson Cancer Center at Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent F. Giusti</last_name>
      <phone>321-841-8588</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic - Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramamoorthy Nagasubramanian</last_name>
      <phone>407-650-7230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Hospital Cancer Institute at Florida Hospital Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803-1273</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Florida Hospital Cancer Institute</last_name>
      <phone>407-303-5623</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic - Pensacola</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey H. Schwartz</last_name>
      <phone>850-505-4790</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>All Children's Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory A. Hale</last_name>
      <phone>727-767-4176</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Cancer Institute at St. Joseph's Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - St. Joseph's Cancer Institute</last_name>
      <phone>800-882-4123</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaplan Cancer Center at St. Mary's Medical Center</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Narayana Gowda</last_name>
      <phone>561-844-6363</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Todd M. Cooper</last_name>
      <phone>404-785-1838</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MBCCOP - Medical College of Georgia Cancer Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912-3730</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen H. McDonough</last_name>
      <phone>706-721-3626</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31403-3089</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Curtis and Elizabeth Anderson Cancer</last_name>
      <phone>912-350-8568</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Research Center of Hawaii</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Cancer Research Center of Hawaii</last_name>
      <phone>808-586-2979</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tripler Army Medical Center</name>
      <address>
        <city>Tripler AMC</city>
        <state>Hawaii</state>
        <zip>96859-5000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa A. Forouhar</last_name>
      <phone>253-968-6144</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mountain States Tumor Institute at St. Luke's Regional Medical Center</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83712-6297</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eugenia Chang</last_name>
      <phone>208-381-2731</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Memorial Hospital - Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stewart Goldman</last_name>
      <phone>773-880-3270</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Chicago Cancer Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - University of Chicago Cancer Research</last_name>
      <phone>773-834-7424</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Illinois Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612-7243</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trial Office - University of Illinois Cancer Center</last_name>
      <phone>312-355-3046</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cardinal Bernardin Cancer Center at Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Cardinal Bernardin Cancer Center</last_name>
      <phone>708-226-4357</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Keyser Family Cancer Center at Advocate Hope Children's Hospital</name>
      <address>
        <city>Oak Lawn</city>
        <state>Illinois</state>
        <zip>60453</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharad N. Salvi</last_name>
      <phone>708-684-4094</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Advocate Lutheran General Cancer Care Center</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60068-1174</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Advocate Lutheran General Cancer Care</last_name>
      <phone>847-384-3621</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Simmons Cooper Cancer Institute</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62794-9677</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Simmons Cooper Cancer Institute</last_name>
      <phone>217-545-7929</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Indiana University Melvin and Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-5289</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Indiana University Cancer Center</last_name>
      <phone>317-274-2552</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Vincent Indianapolis Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - St. Vincent Indianapolis Hospital</last_name>
      <phone>317-338-2194</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Blank Children's Hospital</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Blank Children's Hospital</last_name>
      <phone>515-241-6729</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Holden Comprehensive Cancer Center at University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242-1002</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cancer Information Service</last_name>
      <phone>800-237-1225</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lucille P. Markey Cancer Center at University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536-0093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Markey Cancer Center at University of</last_name>
      <phone>859-257-3379</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kosair Children's Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Kosair Children's Hospital</last_name>
      <phone>502-629-5500</phone>
      <email>CancerResource@nortonhealthcare.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tulane Cancer Center Office of Clinical Research</name>
      <address>
        <city>Alexandria</city>
        <state>Louisiana</state>
        <zip>71315-3198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Tulane Cancer Center</last_name>
      <phone>504-988-6121</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of New Orleans</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Children's Hospital of New Orleans</last_name>
      <phone>504-894-5377</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CancerCare of Maine at Eastern Maine Medical Center</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - CancerCare of Maine</last_name>
      <phone>207-973-4274</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maine Children's Cancer Program at Barbara Bush Children's Hospital</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074-9308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric C. Larsen</last_name>
      <phone>207-396-7565</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alvin and Lois Lapidus Cancer Institute at Sinai Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph M. Wiley</last_name>
      <phone>410-601-6266</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Greenebaum Cancer Center at University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Greenebaum Cancer Center at Universit</last_name>
      <phone>800-888-8823</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Sidney Kimmel Comprehensive Cancer Ce</last_name>
      <phone>410-955-8804</phone>
      <email>jhcccro@jhmi.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Naval Medical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20889-5600</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa A. Forouhar</last_name>
      <phone>253-968-6144</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Floating Hospital for Children at Tufts - New England Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johannes E.A. Wolff</last_name>
      <phone>617-636-5535</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMASS Memorial Cancer Center - University Campus</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher P. Keuker</last_name>
      <phone>508-856-4225</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>C.S. Mott Children's Hospital at University of Michigan Medical Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0286</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - C.S. Mott Children's Hospital</last_name>
      <phone>800-865-1125</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-1379</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Barbara Ann Karmanos Cancer Institute</last_name>
      <phone>313-576-9363</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hurley Medical Center</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Hurley Medical Center</last_name>
      <phone>810-762-8057</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helen DeVos Children's Hospital at Spectrum Health</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Helen DeVos Children's Hospital</last_name>
      <phone>616-391-3050</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Van Elslander Cancer Center at St. John Hospital and Medical Center</name>
      <address>
        <city>Grosse Pointe Woods</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clincial Trials Office - Van Elslander Cancer Center at St. Jo</last_name>
      <phone>313-343-3166</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CCOP - Kalamazoo</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007-5381</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey S. Lobel</last_name>
      <phone>269-341-6350</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Breslin Cancer Center at Ingham Regional Medical Center</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48910</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Breslin Cancer Center at Ingham Regio</last_name>
      <phone>517-334-2765</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital - Royal Oak Campus</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - William Beaumont Hospital - Royal Oak</last_name>
      <phone>248-551-7695</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospitals and Clinics of Minnesota - Minneapolis</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Children's Hospitals and Clinics of M</last_name>
      <phone>612-813-5193</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Masonic Cancer Center at University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Masonic Cancer Center at University o</last_name>
      <phone>612-624-2620</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - All Mayo Clinic Locations</last_name>
      <phone>507-538-7623</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Cancer Clinic</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216-4505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gail C. Megason</last_name>
      <phone>601-984-5220</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ellis Fischel Cancer Center at University of Missouri - Columbia</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trial Office - Ellis Fischel Cancer Center</last_name>
      <phone>573-882-7440</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maxine L. Hetherington</last_name>
      <phone>816-234-3265</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>David C. Pratt Cancer Center at St. John's Mercy</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - David C. Pratt Cancer Center at St. J</last_name>
      <phone>314-251-6770</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cardinal Glennon Children's Hospital</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William S. Ferguson</last_name>
      <phone>314-577-5638</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert J. Hayashi</last_name>
      <phone>314-454-4118</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114-4113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Minnie Abromowitch</last_name>
      <phone>402-955-3950</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UNMC Eppley Cancer Center at the University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-6805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - UNMC Eppley Cancer Center at the Univ</last_name>
      <phone>800-999-5465</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CCOP - Nevada Cancer Research Foundation</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109-2306</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Bernstein</last_name>
      <phone>702-732-1493</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756-0002</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Norris Cotton Cancer Center</last_name>
      <phone>603-650-7609</phone>
      <email>cancerhelp@dartmouth.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center Cancer Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Hackensack University Medical Center</last_name>
      <phone>201-996-2879</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Overlook Hospital</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven L. Halpern</last_name>
      <phone>973-971-6720</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Cancer Institute of New Jersey</last_name>
      <phone>732-235-8675</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Peter's University Hospital</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stanley Calderwood</last_name>
      <phone>732-745-6674</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Newark Beth Israel Medical Center</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Newark Beth Israel Medical Center</last_name>
      <phone>973-926-3136</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital and Medical Center</name>
      <address>
        <city>Paterson</city>
        <state>New Jersey</state>
        <zip>07503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary A. Bonilla</last_name>
      <phone>973-754-3349</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Cancer Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131-5636</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - University of New Mexico Cancer Cente</last_name>
      <phone>505-272-6972</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Albany Medical Center Hospital</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208-3419</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vikramjit S. Kanwar</last_name>
      <phone>518-262-5513x25265</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Roswell Park Cancer Institute</last_name>
      <phone>877-275-7724</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Winthrop University Hospital</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark E. Weinblatt</last_name>
      <phone>516-663-9400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Schneider Children's Hospital</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arlene S. Redner</last_name>
      <phone>718-470-3460</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Birte Wistinghausen</last_name>
      <phone>212-241-7022</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>New York Weill Cornell Cancer Center at Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - New York Weill Cornell Cancer Center</last_name>
      <phone>212-746-1848</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter G. Steinherz</last_name>
      <phone>212-639-7951</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>NYU Cancer Institute at New York University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth A. Raetz</last_name>
      <phone>212-263-8400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>James P. Wilmot Cancer Center at University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa R. Hackney</last_name>
      <phone>585-275-2981</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Cancer Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794-9446</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Stony Brook University Cancer Center</last_name>
      <phone>800-862-2215</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University Hospital</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - SUNY Upstate Medical University Hospi</last_name>
      <phone>315-464-5476</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehmet F. Ozkaynak</last_name>
      <phone>914-493-7997</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mission Hospitals - Memorial Campus</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Mission Hospitals - Memorial Campus</last_name>
      <phone>828-213-4150</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7295</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Lineberger Comprehensive Cancer Cente</last_name>
      <phone>877-668-0683; 919-966-4432</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Presbyterian Cancer Center at Presbyterian Hospital</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28233-3549</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Presbyterian Cancer Center at Presbyt</last_name>
      <phone>704-384-5369</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Blumenthal Cancer Center at Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28232-2861</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Blumenthal Cancer Center at Carolinas</last_name>
      <phone>704-355-2884</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke Comprehensive Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Duke Comprehensive Cancer Center</last_name>
      <phone>888-275-3853</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leo W. Jenkins Cancer Center at ECU Medical School</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Leo W. Jenkins Cancer Center at ECU M</last_name>
      <phone>252-744-2391</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Comprehensive Cancer Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1096</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Wake Forest University  Comprehensive</last_name>
      <phone>336-713-6771</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CCOP - MeritCare Hospital</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathan L. Kobrinsky</last_name>
      <phone>701-234-7544</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akron Children's Hospital</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44308-1062</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Akron Children's Hospital</last_name>
      <phone>330-543-3193</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Cincinnati Children's Hospital Medica</last_name>
      <phone>513-636-2799</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Cleveland Clinic Taussig Cancer Cente</last_name>
      <phone>866-223-8100</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rainbow Babies and Children's Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yousif (Joe) H. Matloub</last_name>
      <phone>216-844-3345</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205-2696</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura T. Martin</last_name>
      <phone>614-722-3582</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dayton Children's - Dayton</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45404-1815</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmett H. Broxson</last_name>
      <phone>937-641-3111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mercy Children's Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rama Jasty</last_name>
      <phone>419-251-8215</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toledo Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Toledo Hospital</last_name>
      <phone>419-824-1842</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oklahoma University Cancer Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rene Y. McNall-Knapp</last_name>
      <phone>405-271-5311</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Natalie Warren Bryant Cancer Center at St. Francis Hospital</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory B. Kirkpatrick</last_name>
      <phone>918-502-6720</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Knight Cancer Institute at Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Knight Cancer Institute at Oregon Hea</last_name>
      <phone>503-494-1080</phone>
      <email>trials@ohsu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Legacy Emanuel Hospital and Health Center and Children's Hospital</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Legacy Emanuel Hospital and Health Ce</last_name>
      <phone>503-413-8199</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Hospital - Muhlenberg</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip M. Monteleone</last_name>
      <phone>484-884-3333</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Geisinger Cancer Institute at Geisinger Health</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822-0001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Geisinger Cancer Institute</last_name>
      <phone>570-271-5251</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Penn State Children's Hospital</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033-0850</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John F. Kuttesch</last_name>
      <phone>717-531-6012</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-9786</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Fox</last_name>
      <phone>267-425-3010</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Christopher's Hospital for Children</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19134-1095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - St. Christopher's Hospital for Childr</last_name>
      <phone>215-427-8991</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Children's Hospital of Pittsburgh</last_name>
      <phone>412-692-7056</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hollings Cancer Center at Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Hollings Cancer Center at Medical Uni</last_name>
      <phone>843-792-9321</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Palmetto Health South Carolina Cancer Center</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Palmetto Health South Carolina Cancer</last_name>
      <phone>803-434-3680</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Greenville Hospital Cancer Center</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Greenville Hospital Cancer Center</last_name>
      <phone>864-241-6251</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sanford Cancer Center at Sanford USD Medical Center</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57117-5039</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Sanford Cancer Center</last_name>
      <phone>605-328-1367</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>T.C. Thompson Children's Hospital</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manoo G. Bhakta</last_name>
      <phone>423-778-7289</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>East Tennessee Children's Hospital</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ray C. Pais</last_name>
      <phone>865-541-8266</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6838</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Vanderbilt-Ingram Cancer Center</last_name>
      <phone>800-811-8480</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Tech University Health Sciences Center School of Medicine - Amarillo</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Osvaldo Regueira</last_name>
      <phone>806-354-5434x282</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dell Children's Medical Center of Central Texas</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78723</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Dell Children's Medical Center of Cen</last_name>
      <phone>512-324-8022</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Driscoll Children's Hospital</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78411</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Driscoll Children's Hospital</last_name>
      <phone>361-694-5311</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical City Dallas Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carl Lenarsky</last_name>
      <phone>972-566-6647x4439</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Simmons Comprehensive Cancer Center a</last_name>
      <phone>866-460-4673; 214-648-7097</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cook Children's Medical Center - Fort Worth</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Cook's Children's Medical Center</last_name>
      <phone>682-885-2103</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center - Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-2399</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick A. Thompson</last_name>
      <phone>832-824-4029</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Covenant Children's Hospital</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Latha Prasannan</last_name>
      <phone>806-725-4840</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Methodist Children's Hospital of South Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-3993</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaime Estrada</last_name>
      <phone>210-575-7268</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul J. Thomas</last_name>
      <phone>210-567-7477</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CCOP - Scott and White Hospital</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guy H. Grayson</last_name>
      <phone>254-724-2006</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Primary Children's Medical Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113-1100</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phillip E. Barnette</last_name>
      <phone>801-662-4700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fletcher Allen Health Care - University Health Center Campus</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Fletcher Allen Health Care</last_name>
      <phone>802-656-8990</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Virginia Cancer Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly P. Dunsmore</last_name>
      <phone>434-924-5105</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inova Fairfax Hospital</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042-3300</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Inova Fairfax Hospital</last_name>
      <phone>703-208-6650</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of The King's Daughters</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507-1971</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric J. Lowe</last_name>
      <phone>757-668-7243</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University Massey Cancer Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298-0037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office -Virginia Commonwealth University Masse</last_name>
      <phone>804-628-1939</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carilion Medical Center for Children at Roanoke Community Hospital</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mandy M. Atkinson</last_name>
      <phone>540-981-7376</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Regional Medical Center - Seattle</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie R. Park</last_name>
      <phone>206-987-2106</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Providence Cancer Center at Sacred Heart Medical Center</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99220-2555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judy L. Felgenhauer</last_name>
      <phone>509-474-2777</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Madigan Army Medical Center - Tacoma</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98431</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa A. Forouhar</last_name>
      <phone>253-968-6144</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mary Bridge Children's Hospital and Health Center - Tacoma</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert G. Irwin</last_name>
      <phone>253-403-3481</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>West Virginia University Health Sciences Center - Charleston</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <zip>25302</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allen R. Chauvenet</last_name>
      <phone>304-388-1552</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Vincent Hospital Regional Cancer Center</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54307-3508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - St. Vincent Hospital Regional Cancer</last_name>
      <phone>920-433-8889</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Paul P. Carbone Comprehensive Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792-6164</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - University of Wisconsin Paul P. Carbo</last_name>
      <phone>608-262-5223</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marshfield Clinic - Marshfield Center</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Marshfield Clinic - Marshfield Center</last_name>
      <phone>800-782-1581 ext. 94457</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Midwest Children's Cancer Center at Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael E. Kelly</last_name>
      <phone>414-456-4170</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Children's Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Irving</last_name>
      <phone>617-3636-8671</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Children's Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francoise M. Mechinaud</last_name>
      <phone>613-9345-4893</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital for Children</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6001</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine H. Cole</last_name>
      <phone>011-6189340-8238</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alberta Children's Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B 6A8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Douglas R. Strother</last_name>
      <phone>403-955-7272</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sunil Jayantilal` S. Desai</last_name>
      <phone>780-407-8829</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's and Women's Hospital of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caron Strahlendorf</last_name>
      <phone>604-875-3576</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rochelle A. Yanofsky</last_name>
      <phone>204-787-4163</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Janeway Children's Health and Rehabilitation Centre</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John P. Hand</last_name>
      <phone>709-777-4799</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>IWK Health Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3J 3G9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret C. Yhap</last_name>
      <phone>902-470-8778</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Centre of Southeastern Ontario at Kingston General Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariana P. Silva</last_name>
      <phone>613-5496666x3833</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Western Ontario</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne E. Cairney</last_name>
      <phone>519-685-8494</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Eastern Ontario</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacqueline M.L. Halton</last_name>
      <phone>613-737-7600x2370</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvain Baruchel</last_name>
      <phone>416-813-7795</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montreal Children's Hospital at McGill University Health Center</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3H 1P3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon B. Abish</last_name>
      <phone>514-412-4400x22219</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allan Blair Cancer Centre at Pasqua Hospital</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4T 7T1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mansoor M. Haq</last_name>
      <phone>306-766-2498</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saskatoon Cancer Centre at the University of Saskatchewan</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Mpofu</last_name>
      <phone>306-655-2744</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Starship Children's Health</name>
      <address>
        <city>Auckland</city>
        <zip>1</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lochie R. Teague</last_name>
      <phone>649-307-4949x22423</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital</name>
      <address>
        <city>Christchurch</city>
        <zip>8140</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael J. Sullivan</last_name>
      <phone>+64-33640744</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Swiss Pediatric Oncology Group Geneva</name>
      <address>
        <city>Geneva</city>
        <zip>1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ayse H. Ozsahin</last_name>
      <phone>0041223824712</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Swiss Pediatric Oncology Group Lausanne</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maja Beck Popovic</last_name>
      <phone>41213141111x43567</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Australia</country>
    <country>Canada</country>
    <country>New Zealand</country>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://cancer.gov/clinicaltrials/COG-AALL0932</url>
    <description>Clinical trial summary from the National Cancer Institute's PDQ® database</description>
  </link>
  <verification_date>October 2011</verification_date>
  <lastchanged_date>October 20, 2011</lastchanged_date>
  <firstreceived_date>August 27, 2010</firstreceived_date>
  <responsible_party>
    <name_title>Gregory H. Reaman</name_title>
    <organization>Children's Oncology Group - Group Chair Office</organization>
  </responsible_party>
  <keyword>untreated childhood acute lymphoblastic leukemia</keyword>
  <keyword>B-cell childhood acute lymphoblastic leukemia</keyword>
  <keyword>Philadelphia chromosome positive childhood precursor acute lymphoblastic leukemia</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>6-Mercaptopurine</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Thioguanine</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
</clinical_study>
